2. Gene
  3. C9 - complement C9 Gene

C9 - complement C9 Gene

  • 基因
  • 蛋白
  • 疾病
  • 相关产品
  • 直系同源

中文名称：补体 C9

种属: Homo sapiens

同用名: C9D; ARMD15

基因 ID: 735 | 基因类型: protein coding

关于 C9

Cytogenetic location: 5p13.1 Genomic coordinates (GRCh38): 5:39,284,140-39,364,495 (from NCBI)

This gene has 7 transcripts (splice variants), 190 orthologues, 39 paralogues and is associated with 4 phenotypes. Restricted expression toward liver (RPKM 365.0).

功能概要

该基因编码补体系统的最后一个组成部分。它参与膜攻击复合体 (MAC) 的形成。 MAC 在细菌膜上组装形成一个孔，从而破坏细菌膜组织。该基因的突变会导致 C9 成分缺乏。[RefSeq 提供，2009 年 2 月]

This gene encodes the final component of the Complement System. It participates in the formation of the Membrane Attack Complex (MAC). The MAC assembles on Bacterial membranes to form a pore, permitting disruption of Bacterial membrane organization. Mutations in this gene cause component C9 deficiency. [provided by RefSeq, Feb 2009]

C9 基因产物(1)

mRNA Protein Name
NM_001737.5 NP_001728.1 complement component C9 preproprotein
基因本体论
  • 分子功能
  • 生物过程
  • 细胞组分
分子功能 GO 注释 逻辑证据 参考文献 来源
enables protein binding IPI
IPI: 通过物理相互作用推断
28514442 GOA
生物过程 GO 注释 逻辑证据 参考文献 来源
involved in cell killing IDA
IDA: 通过直接分析推断
26841934 GOA
involved in protein homooligomerization IDA
IDA: 通过直接分析推断
26841934 GOA
细胞组分 GO 注释 逻辑证据 参考文献 来源
located in extracellular space IDA
IDA: 通过直接分析推断
22832194 GOA
part of membrane attack complex IDA
IDA: 通过直接分析推断
22832194 GOA
part of membrane attack complex IPI
IPI: 通过物理相互作用推断
30552328 GOA
located in plasma membrane IDA
IDA: 通过直接分析推断
26841934 GOA
EXP：通过实验结果推断 IDA：通过直接分析推断 IPI：通过物理相互作用推断 IMP：通过突变表型推断 IGI：通过遗传相互作用推断 IEP：通过表达模式推断

C9 蛋白结构

TSP_1

TSP_1: Thrombospondin type 1 domain (46 - 94)

Ldl_recept_a

Ldl_recept_a: Low-density lipoprotein receptor domain class A (100 - 134)

MACPF

MACPF: MAC/Perforin domain (272 - 501)

  • 0
  • 100
  • 200
  • 300
  • 400
  • 500
  • 559 a.a.
蛋白主名 其他名称

complement component C9

complement component 9

C9 蛋白互作信息

分类
蛋白名称 蛋白编号 互作蛋白 互作蛋白种属 互作蛋白编号 实验方法 参考文献
种属内
C9 P02748 APOE Homo sapiens P02649
Anti Tag CoIP
33961781
种属内
C9 P02748 APOE Homo sapiens P02649
Anti Tag CoIP
28514442
种属间: 跨种属相互作用 种属内: 同种属相互作用

关联疾病

疾病名称 别名
Complement Component 9 Deficiency

C9 Deficiency

C9D

C9 Deficiency With Dermatomyositis
Macular Degeneration, Age-Related, 15

Age Related Macular Degeneration 15

ARMD15

Macular Degeneration, Age-Related, 15, Susceptibility To

Macular Degeneration, Age-Related, Type 15
Immunodeficiency Due To A Late Component Of Complement Deficiency

Immunodeficiency Due To C5 To C9 Component Complement Deficiency

Terminal Complement Pathway Deficiency
Meningococcal Meningitis

Meningitis, Meningococcal

Meningitis Meningococcal

Epidemic Meningitis

Meningitis Due To Neisseria Meningitidis

Meningococcal Meninges Infection

Meningococcal Meningeal Infection

Meningococcal Cerebrospinal Inflammation

Chronic Meningococcal Arachnoiditis

Meningococcal Arachnoiditis

Diplococcal Spinal Meningitis

Diplococcal Meningitis

Meningococcal Cerebrospinal Fever

Meningococcal Cerebrospinal Infection

Meningococcal Spinal Meningitis
Immunoglobulin Heavy-And-Light Chain

Ah/Al Amyloidosis

Ig Heavy-And-Light-Chain Amyloidosis
Eye Disease

Eye Diseases

Abnormality Of The Eye

Toxoplasma Oculopathy
疾病名称 别名
Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Macroglobulinemia Of Waldenstrom

Lymphoplasmacytic Lymphoma With Igm Gammopathy

Lymphoplasmacytic Lymphoma

Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Macroglobulinemia Of Waldenstrom

Lymphoplasmacytic Lymphoma With Igm Gammopathy

Lymphoplasmacytic Lymphoma

相关产品

Approval
生物活性分子 (10)
目录号 产品名 作用方式
纯度 是否罕见病
HY-17356 Fenofibrate 99.93% 是
HY-N6972 Cepharanthine 99.91% 是
HY-B0258 Gemfibrozil 99.91% 是
HY-B1218 Sulfaphenazole Inhibitor 99.83% 否
HY-13463 Avatrombopag Agonist 99.83% 是
HY-B0281A Ranitidine hydrochloride 99.88% 是
HY-100386 Ticlopidine Inhibitor 99.34% 否
HY-B0693 Ranitidine ≥97.0% 否
HY-13463B Avatrombopag hydrochloride Agonist 96.69% 是
HY-13463A Avatrombopag maleate Agonist 99.88% 否
Clinical Phase
生物活性分子 (6)
目录号 产品名 作用方式
纯度 Phase
HY-132581 Tadnersen Inhibitor / Phase 3
HY-N1201 Apigenin 99.22% Phase 2
HY-106379 Lurosetron Antagonist / Phase 2
HY-12946 BI 653048 Inhibitor 99.84% Phase 1
HY-114415 AWZ1066S Inhibitor 98.64% Phase 1
HY-12946A BI 653048 phosphate Inhibitor / Phase 1
Pre-clinical Phase
生物活性分子 (155)
Cat. No. 产品名 作用方式
纯度 是否罕见病
HY-103661 BI-6C9 Inhibitor 98.47% 否
HY-N0904 Ginsenoside C-K Inhibitor 99.92% 否
HY-N0043 Ginsenoside Rd Inhibitor 99.88% 否
HY-15550S 4'-Hydroxy diclofenac-d4 98.92% 否
HY-100738 Ubiquitin Isopeptidase Inhibitor I, G5 Inducer ≥98.0% 否
HY-N0893 Tetrahydrocurcumin 98.96% 否
HY-15550 4'-Hydroxy diclofenac 99.70% 否
HY-15565 APD668 99.10% 否
HY-117026 LKY-047 Inhibitor 98.85% 否
HY-117389 Homocarbonyltopsentin 99.88% 否
HY-148907 CS640 99.43% 否
HY-153898 rTRD01 Inhibitor ≥97.0% 否
HY-14362 GSK-25 Inhibitor 99.68% 否
HY-N1446S Oleic acid-13C 99.95% 否
HY-139345 (S,R,S)-AHPC-CO-C9-acid Chemical 97.64% 否
HY-100641S 4-Hydroxytolbutamide-d9 99.29% 否
HY-114759 MS-PPOH Inhibitor 99.27% 否
HY-148822 Nampt activator-2 Activator 98.80% 否
HY-N0473S3 L-Tyrosine-13C9 99.81% 否
HY-17356R Fenofibrate (Standard) 99.91% 否
HY-144652 IDO1-IN-19 Inhibitor 98.52% 否
HY-157581 MS39 Degrader 99.2% 否
HY-42034 Hydroquinine 99.84% 否
HY-B0158S7 Cytidine-13C9 Chemical 99.10% 否
HY-N0688 Linderane Inhibitor 99.61% 否
HY-128859 EMT inhibitor-2 Inhibitor 99.55% 否
HY-107372S Uridine triphosphate-13C9,15N2 sodium / 否
HY-113359AS2 Uridine 5'-diphosphate-13C9,15N2 dilithium Agonist 99.5% 否
HY-124352 2-Nonyl-3-hydroxy-4-quinolone ≥98.0% 否
HY-125818S3 Cytidine-5'-triphosphate-13C9 dilithium 99.0% 否
HY-132581A Tadnersen sodium Inhibitor 90.06% 否
HY-18063 ML252 Inhibitor 99.9% 否
HY-N0215S11 L-Phenylalanine-13C9,15N Antagonist 99.52% 否
HY-D1422 ER Thermo Yellow ≥95.0% 否
HY-B0258S Gemfibrozil-d6 98.00% 否
HY-100641 4-Hydroxytolbutamide 99.69% 否
HY-107372S2 Uridine triphosphate-13C9 dilithium ≥98.0% 否
HY-116862 Dibenzylfluorescein 99.54% 否
HY-131495 (S)-6-O-Desmethylnaproxen Inhibitor 95.73% 否
HY-B0258R Gemfibrozil (Standard) 99.90% 否
HY-D0184S3 2'-Deoxycytidine-13C9,15N3 99.00% 否
HY-N0215S10 L-Phenylalanine-13C9 Antagonist 98% 否
HY-N1201S Apigenin-d5 98.90% 否
HY-N7057S3 Nonanoic acid-d2 98.63% 否
HY-N8382 Chalepensin Inhibitor ≥98.0% 否
HY-W013175S2 Uridine 5'-monophosphate-13C9,15N2 disodium ≥99.0% 否
HY-Y0123S DL-Tyrosine-13C9,15N ≥98.0% 否
HY-159191S VQPGQN(Phe-13C9,15N)HMFTKEKLEEVIKDI TFA 95.41% 否
HY-W751165 Uridine-13C9,15N2 ≥99.0% 否
HY-135390 Hydroxy desmethyl Bosentan / 否
HY-100386S Ticlopidine-d4 Inhibitor / 否
HY-101400S2 Deoxycytidine triphosphate-13C9,15N3 dilithium Activator / 否
HY-101400S4 Deoxycytidine triphosphate-13C9 dilithium Activator / 否
HY-101981S3 Uridine 5'-monophosphate-13C9,15N2 dilithium / 否
HY-101981S4 Uridine 5'-monophosphate-13C9 dilithium / 否
HY-113359AS1 Uridine 5'-diphosphate-13C9 dilithium Agonist / 否
HY-113400S1 Cytidine diphosphate-13C9 dilithium / 否
HY-113400S2 Cytidine diphosphate-13C9,15N3 dilithium / 否
HY-113887 Prostaglandin F1β / 否
HY-113887A 11β-Prostaglandin F1β Control / 否
HY-116095 CypD-IN-5 Inhibitor / 否
HY-119996 AR-C141990 / 否
HY-125607 Tetranor-PGJM / 否
HY-13463BS Avatrombopag-d8 hydrochloride Agonist / 否
HY-138517 Thiol-C9-PEG7 / 否
HY-138526 Thiol-C9-PEG4-acid / 否
HY-138527 Thiol-C9-PEG4 / 否
HY-138528 Thiol-C9-PEG5-acid / 否
HY-138529 Thiol-C9-PEG5 / 否
HY-141547 Nav1.7-IN-8 Inhibitor / 否
HY-141878 di-Ellipticine-RIBOTAC Modulator / 否
HY-141913S 3-Chlorotyrosine-13C9, 15N hydrochloride / 否
HY-143906 URAT1 inhibitor 2 Inhibitor / 否
HY-147807 HIV-1 inhibitor-40 Inhibitor / 否
HY-148597 FGFR-IN-10 Inhibitor / 否
HY-149866 HIV-1 inhibitor-58 Inhibitor / 否
HY-150710S Cytidine 5'-triphosphate-13C9,15N3 ammonium / 否
HY-151251 CYP2C9/CYP2C19-IN-1 Inhibitor / 否
HY-151253 CYP2C1/CYP2C19-IN-2 Inhibitor / 否
HY-153371 50-C2-C9-4tail / 否
HY-153970 URAT1 inhibitor 7 Inhibitor / 否
HY-155265 Pomalidomide-5-C9-NH2 hydrochloride 98.68% 否
HY-15550S1 4'-Hydroxy diclofenac-13C6 / 否
HY-159143 BChE-IN-33 Inhibitor / 否
HY-160555 (S,R,S)-AHPC-CO-C9-NH2 / 否
HY-160555A (S,R,S)-AHPC-CO-C9-NH2 hydrochloride 98.79% 否
HY-161943 NEU3-IN-1 Inhibitor / 否
HY-163208 VH 032 amide-alkylC9-amine hydrochloride / 否
HY-163816 Antiproliferative agent-53-d3 Inhibitor / 否
HY-167872 Bifeprofen Inhibitor / 否
HY-168235 (S,R,S)-AHPC-Me-amide-C9-acid Degrader / 否
HY-168277 5-Aminothalidomide-C9-Boc / 否
HY-169095 (S,R,S)-AHPC-Me-CO-C9-NH2 / 否
HY-17356G Fenofibrate (GMP) / 否
HY-17356S Fenofibrate-d6 99.70% 否
HY-17356S1 Fenofibrate-d4 / 否
HY-79131S1 Fmoc-Phe-OH-13C9,15N / 否
HY-A0070AS1 Liothyronine-13C9,15N / 否
HY-B0158S5 Cytidine-13C9,15N3 / 否
HY-B0281AS Ranitidine-d6 hydrochloride 97.00% 否
HY-B1422S 9-Aminoacridine-13C6 Inhibitor / 否
HY-D0184S5 2'-Deoxycytidine-13C9 / 否
HY-N0043R Ginsenoside Rd (Standard) Inhibitor / 否
HY-N0215S9 L-Phenylalanine-13C9,15N,d8 Antagonist / 否
HY-N0893S Tetrahydrocurcumin-d6 / 否
HY-N0904R Ginsenoside C-K (Standard) Inhibitor / 否
HY-N1201R Apigenin (Standard) / 否
HY-N6023 Thermopsoside Inhibitor / 否
HY-P5538S EPYFGYSGAFK-13C9,15N3 TFA / 否
HY-P5947 Tat-HA-NR2B9c / 否
HY-RS01759 C9 Human Pre-designed siRNA Set A Pre-designed Sets / 否
HY-RS01760 C9orf72 Human Pre-designed siRNA Set A Pre-designed Sets / 否
HY-RS01761 C9orf78 Human Pre-designed siRNA Set A Pre-designed Sets / 否
HY-RS03460 CYP2C9 Human Pre-designed siRNA Set A Pre-designed Sets / 否
HY-U00048 Bucolome Inhibitor 98.93% 否
HY-W008016S Fmoc-Tyr(tBu)-OH-13C9,15N / 否
HY-W008849S DMT-dC(bz) Phosphoramidite-13C9,15N3 / 否
HY-W009162S1 Cytidine 5′-monophosphate-13C9 dilithium / 否
HY-W009162S5 Cytidine 5′-monophosphate-13C9,15N3 dilithium / 否
HY-W009216S1 2'-Deoxycytidine-5'-monophosphoric acid-13C9,15N3 dilithium / 否
HY-W011090S ((2R,3S,4R,5R)-5-(4-Amino-2-oxopyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl phosphate-13C9,15N3 sodium / 否
HY-W015007S Metyrosine-13C9,15N,d7 Inhibitor / 否
HY-W018386S1 3-​Bromo-​L-​tyrosine-13C9 / 否
HY-W042357S4 Ac-rC Phosphoramidite-13C9 / 否
HY-W042357S6 Ac-rC Phosphoramidite-13C9,15N3 / 否
HY-W048482S1 rU Phosphoramidite-13C9,15N2 / 否
HY-W048482S2 rU Phosphoramidite-13C9 / 否
HY-W127393 N-Nonanoyl-L-homoserine lactone / 否
HY-101399S γ-Glu-(Phe-13C9,15N) / 否
HY-113455S1 9(S)-HODE-13C18 Inducer / 否
HY-116601 6-Hydroxywarfarin / 否
HY-117160 4-trans-Hydroxy-glibenclamide Inhibitor / 否
HY-117925 Personalised postprandial-targeting Inhibitor / 否
HY-124209 9-keto Fluprostenol / 否
HY-124352S 2-Nonyl-3-hydroxy-4-quinolone-d4 / 否
HY-134999 10-Hydroxywarfarin Inhibitor / 否
HY-145490 trans-Hydroxy Glimepiride / 否
HY-149566 Thalidomide-5-O-C9-NH2 hydrochloride 99.59% 否
HY-149572 Thalidomide-4-O-C9-NH2 hydrochloride / 否
HY-150712S Uridine triphosphate-13C9,15N2 dilithium / 否
HY-156133 Dihydrospinosyn A aglycone / 否
HY-156159 Thalidomide-NH-C9-NH2 hydrochloride / 否
HY-164031 Cloperidone Inhibitor / 否
HY-166934S Endosulfan-13C9 sulfate / 否
HY-169119 Antifungal agent 114 Inhibitor / 否
HY-17356S2 Fenofibrate-13C6 / 否
HY-18063A ML252 hydrochloride Inhibitor / 否
HY-B0258S1 Gemfibrozil-d6-1 / 否
HY-B1449S11 Uridine-13C9 / 否
HY-N12962 11S(12R)-EET / 否
HY-N12962A 11R(12S)-EET / 否
HY-W018386AS 3-​Bromo-​L-​tyrosine-13C9,15N TFA / 否
HY-W018801 5-Nitroisoquinoline / 否
HY-W770410 9-PAHSA-13C4 / 否
HY-113623 Pyrenophorol / 否
抗体抑制剂 (1)
Cat. No. 产品名 作用方式
纯度 是否罕见病
HY-P99141 Anti-Mouse LAG-3 Antibody (C9B7W) 95.00% 否

直系同源

种属 基因名 来源 基因 ID
Mus musculus C9 MGD MGI:1098282
Felis catus C9 VGNC VGNC:60238
Macaca mulatta C9 VGNC VGNC:70482
Rattus norvegicus C9 RGD RGD:620319
Bos taurus C9 VGNC VGNC:26647
Canis familiaris C9 VGNC VGNC:38603
Macaca fascicularis C9 NCBI NCBI:102137382
Others C9 NCBI
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z